In one embodiment, the invention relates to processes for producing acesulfame potassium. In one embodiment, the process comprises the step of reacting a first reaction mixture to form an amidosulfamic acid salt such as a trialkyl ammonium amidosulfamic acid salt. The first reaction mixture comprises sulfamic acid, an amine, and smaller amounts, if any, acetic acid, e.g., less than 1 wt % (10000 wppm). In terms of ranges, the first reaction mixture may comprise from 1 wppm to 1 wt % acetic acid. The process further comprises the step of reacting the amidosulfamic acid salt with diketene to form an acetoacetamide salt. In preferred embodiments, the amidosulfamic acid salt formation reaction is conducted at pH levels from 5.5 to 7.0. The process further comprises the step of deriving the acesulfame-K from the acetoacetamide salt.

In one embodiment, the invention relates to processes for producing acesulfame potassium. In one embodiment, the process comprises the step of reacting a first reaction mixture to form an amidosulfamic acid salt such as a trialkyl ammonium amidosulfamic acid salt. The first reaction mixture comprises sulfamic acid, an amine, and smaller amounts, if any, acetic acid, e.g., less than 1 wt % (10000 wppm). In terms of ranges, the first reaction mixture may comprise from 1 wppm to 1 wt % acetic acid. The process further comprises the step of reacting the amidosulfamic acid salt with diketene to form an acetoacetamide salt. In preferred embodiments, the amidosulfamic acid salt formation reaction is conducted at pH levels from 5.5 to 7.0. The process further comprises the step of deriving the acesulfame-K from the acetoacetamide salt.

The present disclosure provides a chlorhexidine-cyclamate complex having a formula [C.sub.22H.sub.32Cl.sub.2N.sub.10][C.sub.6H.sub.12NO.sub.3S].sub.2 having antibacterial and antiplaque properties, together with oral care compositions comprising the complex, and methods of making and using these complexes and compositions.

This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.

This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.

A method for producing a lithium sulfamate which includes (1) reacting a compound (1) represented by the following formula (1):

##STR00001##

wherein X is fluorine, chlorine, bromine, or iodine, with a compound (2) represented by the following formula (2):

##STR00002##

wherein R.sup.1 and R.sup.2 are each individually H or a substituent as defined herein, the substituent optionally containing at least one bi- to hexavalent heteroatom in the structure and being a substituent in which at least one hydrogen atom is optionally replaced with a fluorine atom or a C0-C7 functional group, to obtain a compound (3) represented by the following formula (3):

##STR00003##

wherein R.sup.1 and R.sup.2 are defined as above.

A method for producing a lithium sulfamate which includes (1) reacting a compound (1) represented by the following formula (1):

##STR00001##

wherein X is fluorine, chlorine, bromine, or iodine, with a compound (2) represented by the following formula (2):

##STR00002##

wherein R.sup.1 and R.sup.2 are each individually H or a substituent as defined herein, the substituent optionally containing at least one bi- to hexavalent heteroatom in the structure and being a substituent in which at least one hydrogen atom is optionally replaced with a fluorine atom or a C0-C7 functional group, to obtain a compound (3) represented by the following formula (3):

##STR00003##

wherein R.sup.1 and R.sup.2 are defined as above.

An electrolyte solution containing a compound represented by the following formula (1). In the formula, R.sup.101 and R.sup.102 are each individually a substituent such as a C1-C7 alkyl group, the substituent optionally contains at least one divalent to hexavalent hetero atom in a structure or optionally has a structure obtained by replacing at least one hydrogen atom by a fluorine atom or a C0-C7 functional group, and at least one selected from the group consisting of R.sup.101 and R.sup.102 when both being an alkyl group, contains at least one divalent to hexavalent hetero atom in the structure or has a structure obtained by replacing at least one hydrogen atom by a fluorine atom or a C0-C7 functional group:

##STR00001##

Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.

Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.